Partnerships & Alliances: IBA and SAIC-Frederick partner for NCI trials

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon
IBA (Ion Beam Applications) Molecular inked a contract with SAIC-Frederick for the production and distribution of F-18 Galacto-RGD for National Cancer Institute clinical trials. F-18 Galacto-RGD (a fluorine-18 labeled peptide) is a PET imaging agent that can be used for noninvasive determination of avB3 integrin expression. The integrin avB3 is a decisive factor in determining grown of a tumor and metastatic potential.